Vyvanse Approved for Adolescent ADHD
MONDAY, Nov. 15 (HealthDay News) -- Vyvanse (lisdexamfetamine dimesylate) capsules have been approved by the U.S. Food and Drug Administration to treat attention deficit hyperactivity disorder (ADHD) among adolescents aged 13 to 17, maker Shire Pharmaceuticals said Monday.
Read more on HealthDay via Yahoo!
没有评论:
发表评论